newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - SEPTERNA INC

  • Financial Performance:

    • No specific revenue, earnings, cash flow, or debt figures were disclosed; the company is pre-revenue and focused on clinical-stage asset development.
    • Financial highlights regarding the partnership with Novo are mentioned as "working well" with the first development candidate selected, but no financial terms or milestones were detailed.
    • The company is currently in the Phase 1 development phase for its lead programs, implying capital expenditure on clinical trials rather than commercial sales.
  • Guidance and Future Outlook:

    • SCP-479 (Hyperparathyroidism): Phase 1 trial readout expected in Q1 2027; Phase 2 trial anticipated in the second half of 2026.
    • SCP-204 (Graves' Disease/Thyroid Eye Disease): Phase 1 trial initiation scheduled for Q1 2027; healthy volunteer data expected by end of 2027.
    • SCP-631 (Mast Cell/X2): Currently between Phase 1 and Phase 2; strategy involves smaller, signal-finding studies to identify new indications like migraine before expanding to Phase 2.
    • Novo Partnership: First development candidate from the five-target collaboration selected and moving forward; ongoing work on four concurrent programs.
  • Business Segments and Product Lines:

    • SCP-479: Oral small molecule targeting PTH1R for hyperparathyroidism; preclinical data shows 80% reduction in endogenous PTH and stable calcium control; distinct from injectable competitors as an oral daily dose.
    • SCP-204: Oral small molecule targeting TSHR for Graves' disease and thyroid eye disease; preclinical data demonstrates normalization of thyroid hormones, reversal of thyroid histology, and reduction of orbital proptosis.
    • SCP-631: Negative allosteric modulator targeting MRG-Perox-2 (Mast Cell X2); completed Phase 1 with a unique mechanism offering near-complete (99%) receptor occupancy and slow off-rate.
    • Osteoporosis Program: Second PTH receptor small molecule agonist in development; designed as a short-acting compound to stimulate bone formation, contrasting with the long-acting profile of SCP-479.
  • Market and Competitive Landscape:

    • Hyperparathyroidism: Market size estimated at 70,000–80,000 patients in the US; current standard of care involves calcium/vitamin D supplements or daily injections (e.g., YorvPath); unmet need exists for oral alternatives to improve adherence for long-term therapy.
    • Differentiation: SCP-479 targets post-surgical patients lacking parathyroid tissue, whereas competitor Encallerate (calcium-sensing receptor agonist) requires intact parathyroid tissue, making the mechanisms incompatible for the target population.
    • Graves' Disease: High unmet need with frequent relapse on antithyroid drugs and limited options for thyroid eye disease; SCP-204 targets the TSHR autoantibody binding site directly.
    • Mast Cell Diseases: Potential pivot to migraine and other conditions (interstitial cystitis, asthma) due to failure in Chronic Spontaneous Urticaria (CSU) and emerging data linking mast cells to migraine.
  • Risks and Challenges:

    • Drug Discovery Complexity: Developing oral small molecules for GPCRs (specifically PTH1R) has historically been difficult, with many large pharma companies failing to find effective compounds.
    • Clinical Translation: Phase 1 trials are in healthy volunteers with intact parathyroid/thyroid glands; while biology is similar to patients, the feedback loops and disease states differ significantly (post-surgical vs. intact).
    • Indication Selection: Shift in strategy for SCP-631 from large Phase 2 CSU studies to smaller signal-finding studies indicates risk in validating new indications like migraine.
    • Dosing Uncertainty: For SCP-204, dose options must be validated to differentiate between normalizing thyroid function versus fully suppressing it.
  • Management Commentary and Tone:

    • Tone: Confident and optimistic regarding the Native Complex Platform's ability to solve historical challenges in GPCR drug discovery.
    • Strategic Clarity: Management emphasized the strategic pivot for SCP-631 to signal-finding studies and highlighted the differentiation of SCP-479 against Encallerate's mechanism of action.
    • Long-term Vision: Emphasis on expanding the treatable patient population for hyperparathyroidism via oral therapy, addressing the burden of daily injections over decades of treatment.
  • Analyst Questions and Answers:

    • Q: Why develop an oral small molecule for PTH1R when it is difficult? A: Historical failure of many companies; SEPTURNA is the only entity with a small molecule mimicking peptide efficacy in preclinical models.
    • Q: How will the Phase 1 data inform the hyperparathyroidism dose? A: Targeting ~50% reduction in endogenous PTH and 0.5 mg/dL increase in serum calcium as a starting dose, comparable to YorvPath's Phase 1 data.
    • Q: What is the titration strategy? A: Will mirror injectable peptides, starting low and titrating up while reducing calcium/vitamin D supplements over several weeks.
    • Q: How does Encallerate compare? A: Different mechanism (calcium-sensing receptor) requiring intact parathyroid tissue; not suitable for the post-surgical population SEPTURNA targets.
    • Q: Why the shift in SCP-631 strategy? A: CSU data was negative; new evidence points to mast cells in migraine and other conditions, warranting smaller, targeted signal-finding studies.
  • Other Key Points:

    • Half-life: SCP-479 demonstrated a 3–4 day half-life in monkeys (targeting 40–80 hours), enabling once-daily dosing; SCP-204 projected 20–40 hours half-life.
    • Safety: Both SCP-479 and SCP-204 showed good tolerability in toxicology studies, with effects consistent with "exaggerated on-target pharmacology" (e.g., hypothyroidism or PTH suppression).
    • Platform Technology: The Native Complex Platform identified two distinct binding pockets for the PTH receptor, allowing small molecules to mimic peptide function effectively.
    • Biomarkers: For Graves' disease trials, expect endogenous TSH levels to rise as a primary biomarker of efficacy.
Company
SEPTERNA INC
Keywords
SEPTERNA INC